<SEC-DOCUMENT>0001140361-22-027931.txt : 20220803
<SEC-HEADER>0001140361-22-027931.hdr.sgml : 20220803
<ACCEPTANCE-DATETIME>20220803080212
ACCESSION NUMBER:		0001140361-22-027931
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20220803
DATE AS OF CHANGE:		20220803

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CATALYST BIOSCIENCES, INC.
		CENTRAL INDEX KEY:			0001124105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				562020050
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51173
		FILM NUMBER:		221130985

	BUSINESS ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-871-0761

	MAIL ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGACEPT INC
		DATE OF NAME CHANGE:	20000919
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>edge20002003x11.htm
<DESCRIPTION>FORM DEFA14A
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 22.7.2.5062
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div>
      <div style="text-align: center; font-size: 14pt; font-weight: bold;">
        <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;" align="center">UNITED STATES</div>
    </div>
    <div style="text-align: center; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div>
      <div style="text-align: center; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
      <div><br>
      </div>
    </div>
    <div>
      <div style="text-align: center; font-size: 18pt; font-weight: bold;">SCHEDULE 14a</div>
    </div>
    <div style="text-align: center; font-size: 12pt; font-weight: bold;">(RULE 14a-101)</div>
    <div>
      <div><br>
      </div>
      <div style="text-align: center; font-size: 12pt; font-weight: bold;">SCHEDULE 14A INFORMATION</div>
      <div><br>
      </div>
    </div>
    <div>
      <div style="text-align: center;">Proxy Statement Pursuant to Section 14(a) of</div>
      <div style="text-align: center;">the Securities Exchange Act of 1934</div>
      <div><br>
      </div>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z7f88ab7fbf704f6b81757ed83eb64027" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td colspan="2" style="vertical-align: bottom;">
            <div>Filed by the Registrant &#9746;</div>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: bottom;">
            <div>
              <div>Filed by a Party other than the Registrant &#9744;</div>
            </div>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: bottom;">
            <div>Check the appropriate box:</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: bottom;">&#9744;</td>
          <td style="width: 97%; vertical-align: bottom;">
            <div>Preliminary proxy statement</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: bottom;">&#9744;</td>
          <td style="width: 97%; vertical-align: bottom;">
            <div style="font-weight: bold;">Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2))</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: bottom;">&#9744;</td>
          <td style="width: 97%; vertical-align: bottom;">
            <div>Definitive Proxy Statement</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: bottom;">&#9746;</td>
          <td style="width: 97%; vertical-align: bottom;">
            <div>Definitive Additional Materials</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: bottom;">&#9744;</td>
          <td style="width: 97%; vertical-align: bottom;">
            <div>Soliciting Material Pursuant to Sec.240.14a-12</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z947dc221242249bdbc9acb6feb09728b" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 100%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-size: 24pt; font-weight: bold;">CATALYST BIOSCIENCES, INC.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: bottom;">
            <div style="text-align: center;">(Name of Registrant as Specified in its Charter)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: bottom;">
            <div style="text-align: center;">(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z46388b6d280849459775746d07565673" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td colspan="2" style="vertical-align: bottom;">
            <div>Payment of Filing Fee (Check the appropriate box):</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: bottom;">&#9746;</td>
          <td style="width: 97%; vertical-align: bottom;">
            <div>No fee required.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: bottom;">&#9744;</td>
          <td style="width: 97%; vertical-align: bottom;">
            <div>Fee paid previously with preliminary materials.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: bottom;">&#9744;</td>
          <td style="width: 97%; vertical-align: bottom;">
            <div>Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11</div>
          </td>
        </tr>

    </table>
    <div>
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div>On August 3, 2022, Catalyst Biosciences, Inc. issued the press release below.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Catalyst Stockholders Vote &#8220;FOR&#8221; All of the Company&#8217;s Nominees on the WHITE Proxy Card</div>
    <div><br>
    </div>
    <div style="text-align: center; font-style: italic;">ISS and Glass Lewis Highlight That Stockholders Are Best Served by Allowing the Incumbent Board to Pursue Its Cash Distribution Plan</div>
    <div><br>
    </div>
    <div style="text-align: center; font-style: italic;">Catalyst Urges Stockholders to VOTE &#8220;FOR&#8221; All of the Company&#8217;s Nominees</div>
    <div><br>
    </div>
    <div>SOUTH SAN FRANCISCO, Calif., August 3, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the &#8220;Company,&#8221; &#8220;Catalyst&#8221; or &#8220;we&#8221;) today announced that leading proxy advisory firms Institutional Shareholder Services Inc. (&#8220;ISS&#8221;) and
      Glass Lewis have recommended that Catalyst stockholders vote FOR all of the Company&#8217;s nominees on the WHITE proxy card in advance of Catalyst&#8217;s upcoming 2022 Annual Meeting of Stockholders (the &#8220;Annual Meeting&#8221;), scheduled to be held on August 15,
      2022.</div>
    <div><br>
    </div>
    <div>In its report, ISS specifically noted:<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup></div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf92db84482154d7cbb15a406dd1e2ca2" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>&#8220;In light of the board&#8217;s success at selling the complement portfolio for more than the market&#8217;s expectations, and its commitment to make an initial cash distribution to shareholders following the resolution of the dissident&#8217;s proxy contest
              and litigation, shareholders appear to be best served by encouraging the board to continue pursuing its existing plan.&#8221;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0851803648024e1392b487d6c74a8729" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>&#8220;[T]he presence on the board of two independent directors appointed as part of a settlement with the dissident in 2020 (one of whom, [Dr. Geoffrey] Ling, was selected by the dissident), and the addition of a shareholder representative as
              an observer, appear to be sufficient safeguards to allow the incumbent directors to proceed with their stated plan.&#8221;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc9f5ec7b913f4435bcb87d97ad5666ac" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>&#8220;[I]t is preferable to allow the incumbent board an opportunity to continue with its plan to return available cash and attempt to monetize remaining assets over the next year.&#8221;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>In its report, Glass Lewis specifically noted:<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup></div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1db8f15375e9401ca41298167af875ad" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>&#8220;Given that the board has already implemented (or committed to substantially implement) the Dissident&#8217;s core suggestions for the Company, we believe there is insufficient basis to support the Dissident&#8217;s campaign for further board seats at
              this time.&#8221;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd0b17391b85c493390f15691f1a18b9d" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>&#8220;We also agree with the board that the Dissident Nominees lack both relevant industry-specific experience and sufficient independence from the Dissident.&#8221;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0461280e7b494a9fb77fb696ac9aac50" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>&#8220;[B]ased on the biographical information presented by the Dissident, it&#8217;s unclear to us whether the Dissident Nominees have any substantive experience at other firms that could be viewed as a close parallel to the Company&#8217;s current
              situation (i.e., situations involving the successful divestment of assets and a significant return of capital to investors).&#8221;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2997b112eda44f528f9305a5474c7597" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>&#8220;[W]e recommend that shareholders vote on the Company&#8217;s WHITE proxy card FOR all nominees.&#8221;</div>
          </td>
        </tr>

    </table>
    <br>
    <hr style="background-color: #000000; border: 0px; height: 1px; width: 2in; margin-left: 0pt; margin-right: auto; color: #000000;" align="left" noshade="noshade">
    <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup> ISS and Glass Lewis reports, August 2, 2022. Permission to use quotes neither sought nor obtained.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div>On behalf of the Board, Nassim Usman, Ph.D., Chief Executive Officer of Catalyst Biosciences, commented, &#8220;We are pleased that both ISS and Glass Lewis have recommended that Catalyst stockholders support the reelection of our three nominees.
      Augustine Lawlor, Dr. Geoffrey Ling and Eddie Williams are highly qualified leaders, each of whom played an important role in developing our Cash Distribution Plan and is fully committed to implementing the Plan for the benefit of all stockholders.&#8221;</div>
    <div><br>
    </div>
    <div>Catalyst stockholders are reminded that their support is crucial, regardless of how many shares they own. To follow the recommendation of ISS, Glass Lewis and of our Board, <font style="font-weight: bold;">stockholders should support Catalyst&#8217;s
        Board of Directors and the Cash Distribution Plan <u>TODAY</u>.</font></div>
    <div><br>
    </div>
    <div style="text-align: center;">Vote <font style="font-weight: bold;">&#8220;FOR&#8221; ALL</font> nominees on the <font style="font-weight: bold;"><u>WHITE</u></font> proxy card.</div>
    <div><br>
    </div>
    <div style="font-weight: bold;">About Catalyst Biosciences</div>
    <div>Catalyst is a biotechnology company focused on protease therapeutics to address unmet medical needs in disorders of the complement and coagulation systems. After the transaction of its complement pipeline, Catalyst&#8217;s product candidates consist of
      the coagulation related assets marzeptacog alfa (activated) (&#8220;MarzAA&#8221;), dalcinonacog alfa (&#8220;DalcA&#8221;), and CB 2679d-GT. MarzAA is a SQ administered next generation engineered coagulation Factor VIIa (&#8220;FVIIa&#8221;) for the treatment of episodic bleeding and
      prophylaxis in subjects with rare bleeding disorders. DalcA is a next-generation SQ administered FIX. CB 2679d-GT is an AAV-based gene therapy construct harboring the DalcA sequence. Both MarzAA and DalcA have shown sustained efficacy and safety in
      mid-stage clinical trials and are available for partnering. CB 2679d-GT has obtained preclinical proof-of-concept and is also available for partnering.</div>
    <div><br>
    </div>
    <div style="font-weight: bold;">Additional Information and Where to Find It</div>
    <div>Catalyst Biosciences, Inc. (the &#8220;Company&#8221;) has filed a definitive proxy statement, an accompanying WHITE proxy card and other relevant documents with the Securities and Exchange Commission (the &#8220;SEC&#8221;) in connection with the solicitation of proxies
      for the Company&#8217;s 2022 annual meeting of stockholders (the &#8220;Annual Meeting&#8221;). BEFORE MAKING ANY VOTING DECISION, STOCKHOLDERS OF THE COMPANY ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING THE COMPANY&#8217;S
      DEFINITIVE PROXY STATEMENT AND ANY AMENDMENTS AND SUPPLEMENTS THERETO, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and stockholders will be able to obtain a copy of the definitive proxy statement and other documents filed by the
      Company with the SEC free of charge from the SEC&#8217;s website at www.sec.gov. In addition, copies will be available at no charge by selecting &#8220;Financials &amp; Filings&#8221; in the &#8220;Investors&#8221; tab of the Company&#8217;s website at www.catalystbiosciences.com.</div>
    <div><br>
    </div>
    <div style="font-weight: bold;">Certain Information Regarding Participants in the Solicitation</div>
    <div>The Company, its directors and certain of its executive officers will be participants in the solicitation of proxies from the Company&#8217;s stockholders in connection with the Annual Meeting. The names of these directors and executive officers and
      their respective direct and indirect interests, by security holdings or otherwise, in the Company are set forth in the Company&#8217;s definitive proxy statement filed with the SEC on July 19, 2022.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="font-weight: bold;">Forward-Looking Statements</div>
    <div>This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include, without limitation, those regarding the amount and timing of planned cash distributions, potential uses of
      and markets for MarzAA, DalcAA and CB 2679-GT, and Catalyst&#8217;s plans to continue to explore strategic alternatives. Actual results or events could differ materially from the plans, intentions, expectations, and projections disclosed in the
      forward-looking statements. Various important factors could cause actual results or events to differ materially, including, but not limited to, the risks that Catalyst&#8217;s obligations and liabilities will be greater than currently anticipated, that the
      pending litigation and anticipated proxy contest with JDS1 will not be resolved in a timely manner and the expenses associated with that litigation will be greater than anticipated, that Catalyst will not be able to identify strategic partners
      interested in MarzAA, DalcAA, CB 2679-GT or any other transaction with the Company, and other risks described in the &#8220;Risk Factors&#8221; section of the Company&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on
      March 31, 2022, the Quarterly Report on Form 10-Q filed with the SEC on May 9, 2022, and in other filings filed from time to time with the SEC. The Company does not assume any obligation to update any forward-looking statements, except as required by
      law.</div>
    <div><br>
    </div>
    <div style="font-weight: bold;">Contact Information</div>
    <div>Trisha Colton</div>
    <div>Catalyst Biosciences, Inc.</div>
    <div>investors@catbio.com</div>
    <div> <br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
